Wierda, W. G., Shah, N. N., Cheah, C. Y., Lewis, D., Hoffman, M. S., Coombs, C. C., … Al-Sawaf, O. (2024). Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study. In ONCOLOGY RESEARCH AND TREATMENT (Vol. 47, pp. 120–121).

Wierda, William G., Nirav N. Shah, Chan Y. Cheah, David Lewis, Marc S. Hoffman, Catherine C. Coombs, Nicole Lamanna, et al. “Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study.” In ONCOLOGY RESEARCH AND TREATMENT, 47:120–21, 2024.

Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffman MS, Coombs CC, et al. Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study. In: ONCOLOGY RESEARCH AND TREATMENT. 2024. p. 120–1.

Wierda, William G., et al. “Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study.” ONCOLOGY RESEARCH AND TREATMENT, vol. 47, 2024, pp. 120–21.

Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffman MS, Coombs CC, Lamanna N, Shuo MA, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes J, Mckinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar A, Patel MR, Seymour JF, Woyach J, Roeker LE, Thompson PA, Abada P, Ho C, Marella N, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Ghia P, Al-Sawaf O. Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study. ONCOLOGY RESEARCH AND TREATMENT. 2024. p. 120–121.